Status:
NOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?
Lead Sponsor:
Assiut University
Conditions:
Leukaemia (Chronic)
Eligibility:
All Genders
18-65 years
Brief Summary
Evaluation of the impact of various TKI on thyroid function in patients diagnosed with cml
Detailed Description
Tyrosine kinase inhibitors (TKIs) block the phosphorylation pathways of cellular signaling proteins, essential for tumor cell proliferation . Several endocrine side efects have been described with the...
Eligibility Criteria
Inclusion
- Patients age from 18 to 65 year
- Newly diagnosed CML patients with Philadelphia chromosome positive based on peripheral blood findings and molecular analysis for the BCR-ABL mutation initiating ttt with a TKI (Philadelphia chromosome positive. CML patients )
Exclusion
- -any history of using drugs interfering with TKI or having effect on thyroid function (Dexamethasone, Phenytoin, Carbamazepine, Rifampin and Phenobarbital)
- Patients with a history of thyroid disease ( hypo or hyperthyroidism or auto immunity )or are already on treatment for thyroid dysfunction
- pregnancy and lactation
- concomitant use of oral contraceptive pills or corticosteroids.
- Other malignancies requiring concurrent treatment
- previous ttt with TKI
Key Trial Info
Start Date :
November 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT07200882
Start Date
November 1 2025
End Date
December 1 2027
Last Update
October 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.